Trial · NCT07895160
Organ Culture for Endocrine Resistant Next Line: A Treatment Selection Study in Metastatic Breast Cancer
NCT07895160, Not applicable, Recruiting, Tel-Aviv Sourasky Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Organ Culture for Endocrine Resistant Next Line: A Treatment Selection Study in Metastatic Breast Cancer. Trials, record NCT07895160. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07895160
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Organ Culture for Endocrine Resistant Next Line: A Treatment Selection Study in Metastatic Breast Cancer
- NCT number
- NCT07895160
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 39 participants, estimated
- Lead sponsor
- Tel-Aviv Sourasky Medical Center
- Conditions
- Metastatic Breast Cancer, Hormon Receptor Positive Breast Cancer
- Interventions
- cResponse Ex Vivo Organ Culture (EVOC) Drug Sensitivity Assay
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate (ORR) | From initiation of assay-guided treatment through study completion, an estimated average of 1 year. | The proportion of evaluable participants achieving a complete response (CR) or partial response (PR) according to RECIST version 1.1 following systemic anticancer treatment selected using the cResponse ex vivo organ culture (EVOC) drug sensitivity assay. The response rate will be calculated among participants with an assay result indicating sensitivity to at least one tested treatment, as specified in the study protocol. Tumor response will be assessed approximately every 8 weeks until disease progression or treatment discontinuation. |
| Secondary | Progression-Free Survival (PFS) | From initiation of assay-guided treatment through study completion, an estimated average of 1 year. | Progression-free survival (PFS) is defined as the time from initiation of assay-guided systemic anticancer treatment to the first documented disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first. Disease progression will be assessed approximately every 8 weeks. Participants without documented progression or death will be censored at the date of their last adequate disease assessment. |
| Secondary | Overall Survival (OS) | From initiation of assay-guided treatment until death from any cause or end of follow-up, up to 24 months. | Overall survival (OS) is defined as the time from initiation of assay-guided systemic anticancer treatment to death from any cause. Participants who are alive at the time of analysis will be censored at the date they were last known to be alive. |
| Secondary | Clinical Benefit Rate (CBR) | From initiation of assay-guided treatment through study completion, an estimated average of 1 year. | Clinical benefit rate (CBR) is defined as the proportion of evaluable participants achieving complete response (CR), partial response (PR), or stable disease (SD) of the protocol-defined minimum duration, according to RECIST version 1.1, following assay-guided systemic anticancer treatment. Tumor response will be assessed approximately every 8 weeks until disease progression or treatment discontinuation. |
| Secondary | Correlation Between cResponse Drug Sensitivity Score and Clinical Tumor Response | From assay testing through study completion, an estimated average of 1 year. | Correlation between the quantitative drug sensitivity score (range: 1-100; unitless, with higher scores indicating greater predicted drug sensitivity), generated by the cResponse ex vivo organ culture (EVOC) assay using a proprietary algorithm, and observed clinical tumor response to the selected treatment, assessed according to RECIST version 1.1. Clinical response will be categorized as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). The correlation will be quantified using Spearman's rank correlation coefficient (range: -1 to +1; unitless). |
| Secondary | Second Progression-Free Survival (PFS2) | From initiation of assay-guided treatment through study completion, an estimated average of 2 years. | Second progression-free survival (PFS2) is defined as the time from initiation of assay-guided systemic anticancer treatment to the second documented disease progression, occurring during or after subsequent anticancer treatment, or death from any cause, whichever occurs first. Participants without a documented PFS2 event will be censored at the date of their last adequate disease assessment, according to the study protocol. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07895160
GET https://conductscience.org/api/trials/v1/NCT07895160/registered